Do analysts rate CARM or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer EVGN or KTTA?

Pasithea Therapeutics has a consensus target price of $3.00, indicating a potential upside of 485.14%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend ALVR or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ALVR or EVGN?

Evogene has higher revenue and earnings than AlloVir. Evogene is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Evogene $3.85M 1.02 -$8.48M -$0.91 N/A

Is ALVR or EVGN more profitable?

AlloVir has a net margin of 0.00% compared to Evogene's net margin of -694.18%. AlloVir's return on equity of -71.03% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Evogene -694.18% -156.53% -86.80%

Do analysts prefer EVGN or APLT?

Applied Therapeutics has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media prefer EVGN or APLT?

In the previous week, Evogene and Evogene both had 1 articles in the media. Evogene's average media sentiment score of 0.00 equaled Applied Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evogene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Applied Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend EVGN or PASG?

Passage Bio has a consensus target price of $13.25, indicating a potential upside of 165.00%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11

Is EVGN or PASG more profitable?

Passage Bio has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Evogene's return on equity of -156.53% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Evogene -694.18% -156.53% -86.80% Passage Bio N/A -218.59% -72.93%

Does the media refer more to EVGN or PASG?

In the previous week, Evogene and Evogene both had 1 articles in the media. Evogene's average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evogene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Evogene (EVGN) Competitors

$0.45 -0.04 (-8.35%)

Closing price 09/23/2026 03:46 PM Eastern

Extended Trading

$0.46 +0.01 (+2.81%)

As of 09/23/2026 06:15 PM Eastern

Compare

EVGN vs. CARM, KTTA, ALVR, APLT, and PASG

Should you buy Evogene stock or one of its competitors? Evogene's main competitors and comparable companies include Carisma Therapeutics (CARM), Pasithea Therapeutics (KTTA), AlloVir (ALVR), Applied Therapeutics (APLT), and Passage Bio (PASG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Evogene compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -694.18%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Evogene	-694.18%	-156.53%	-86.80%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Carisma Therapeutics has a beta of -9.02, indicating that its stock price is 1,002% less volatile than the broader market. Comparatively, Evogene has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

In the previous week, Evogene had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 1 mentions for Evogene and 0 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 0.00 equaled Evogene'saverage media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Evogene	Neutral

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 7.4% of Evogene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Evogene	$3.85M	1.02	-$8.48M	-$0.91	N/A

Summary

Carisma Therapeutics and Evogene tied by winning 6 of the 12 factors compared between the two stocks.

How does Evogene compare to Pasithea Therapeutics?

Evogene (NASDAQ:EVGN) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Evogene has higher revenue and earnings than Pasithea Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.02	-$8.48M	-$0.91	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A

Pasithea Therapeutics has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Pasithea Therapeutics' return on equity of -49.49% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-694.18%	-156.53%	-86.80%
Pasithea Therapeutics	N/A	-49.49%	-46.81%

Evogene has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Pasithea Therapeutics has a consensus target price of $3.00, indicating a potential upside of 485.14%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Evogene had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 1 mentions for Evogene and 0 mentions for Pasithea Therapeutics. Evogene's average media sentiment score of 0.00 equaled Pasithea Therapeutics'average media sentiment score.

Company	Overall Sentiment
Evogene	Neutral
Pasithea Therapeutics	Neutral

10.4% of Evogene shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Pasithea Therapeutics beats Evogene on 8 of the 14 factors compared between the two stocks.

How does Evogene compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Evogene has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

AlloVir has a net margin of 0.00% compared to Evogene's net margin of -694.18%. AlloVir's return on equity of -71.03% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Evogene	-694.18%	-156.53%	-86.80%

Evogene has higher revenue and earnings than AlloVir. Evogene is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Evogene	$3.85M	1.02	-$8.48M	-$0.91	N/A

In the previous week, Evogene had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Evogene and 0 mentions for AlloVir. AlloVir's average media sentiment score of 0.00 equaled Evogene'saverage media sentiment score.

Company	Overall Sentiment
AlloVir	Neutral
Evogene	Neutral

66.1% of AlloVir shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

AlloVir and Evogene tied by winning 6 of the 12 factors compared between the two stocks.

How does Evogene compare to Applied Therapeutics?

Evogene (NASDAQ:EVGN) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Evogene has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

In the previous week, Evogene and Evogene both had 1 articles in the media. Evogene's average media sentiment score of 0.00 equaled Applied Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evogene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Applied Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Applied Therapeutics has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

10.4% of Evogene shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Applied Therapeutics has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Evogene's return on equity of -156.53% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-694.18%	-156.53%	-86.80%
Applied Therapeutics	N/A	-340.84%	-175.00%

Evogene has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.02	-$8.48M	-$0.91	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Summary

Applied Therapeutics beats Evogene on 7 of the 13 factors compared between the two stocks.

How does Evogene compare to Passage Bio?

Evogene (NASDAQ:EVGN) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Evogene has higher revenue and earnings than Passage Bio. Evogene is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.02	-$8.48M	-$0.91	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.32	N/A

10.4% of Evogene shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 7.4% of Evogene shares are held by insiders. Comparatively, 4.9% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Passage Bio has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Evogene's return on equity of -156.53% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-694.18%	-156.53%	-86.80%
Passage Bio	N/A	-218.59%	-72.93%

In the previous week, Evogene and Evogene both had 1 articles in the media. Evogene's average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evogene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evogene has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Passage Bio has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

Passage Bio has a consensus target price of $13.25, indicating a potential upside of 165.00%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

Summary

Passage Bio beats Evogene on 8 of the 13 factors compared between the two stocks.

Get Evogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVGN vs. The Competition

Export

Metric	Evogene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.30M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.50	13.88	274.02	25.69
Price / Sales	1.02	1,311.42	632.76	76.07
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.33	15.30	10.44	6.32
Net Income	-$8.48M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-10.13%	-1.71%	-0.66%	0.17%
1 Month Performance	-19.09%	-6.17%	-3.16%	-3.27%
1 Year Performance	-61.34%	30.64%	15.15%	5.58%

Evogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVGN Evogene	1.3284 of 5 stars	$0.45 -8.3%	N/A	-61.4%	$4.30M	$3.85M	N/A	52	Gap Down
CARM Carisma Therapeutics	0.3455 of 5 stars	$0.00 flat	N/A	-99.8%	$33K	$10.77M	0.00	20	Gap Down
KTTA Pasithea Therapeutics	2.3842 of 5 stars	$0.50 -2.0%	$3.00 +500.0%	-29.7%	$17.04M	N/A	N/A	3	Analyst Forecast
ALVR AlloVir	N/A	$3.30 -2.4%	N/A	-26.4%	$16.64M	N/A	N/A	110	High Trading Volume
APLT Applied Therapeutics	1.3594 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVGN) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evogene (EVGN) Competitors

EVGN vs. CARM, KTTA, ALVR, APLT, and PASG

How does Evogene compare to Carisma Therapeutics?

Summary

How does Evogene compare to Pasithea Therapeutics?

Summary

How does Evogene compare to AlloVir?

Summary

How does Evogene compare to Applied Therapeutics?

Summary

How does Evogene compare to Passage Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evogene (EVGN) Competitors

EVGN vs. CARM, KTTA, ALVR, APLT, and PASG

How does Evogene compare to Carisma Therapeutics?

Is CARM or EVGN more profitable?

Do analysts rate CARM or EVGN?

Which has more volatility and risk, CARM or EVGN?

Does the media favor CARM or EVGN?

Do insiders and institutionals hold more shares of CARM or EVGN?

Which has better valuation and earnings, CARM or EVGN?

Summary

How does Evogene compare to Pasithea Therapeutics?

Which has stronger earnings and valuation, EVGN or KTTA?

Is EVGN or KTTA more profitable?

Which has more risk & volatility, EVGN or KTTA?

Do analysts prefer EVGN or KTTA?

Does the media refer more to EVGN or KTTA?

Do insiders and institutionals have more ownership in EVGN or KTTA?

Summary

How does Evogene compare to AlloVir?

Do analysts recommend ALVR or EVGN?

Which has more volatility & risk, ALVR or EVGN?

Is ALVR or EVGN more profitable?

Which has preferable earnings and valuation, ALVR or EVGN?

Does the media prefer ALVR or EVGN?

Do institutionals and insiders have more ownership in ALVR or EVGN?

Summary

How does Evogene compare to Applied Therapeutics?

Which has more risk & volatility, EVGN or APLT?

Does the media prefer EVGN or APLT?

Do analysts prefer EVGN or APLT?

Do insiders and institutionals have more ownership in EVGN or APLT?

Is EVGN or APLT more profitable?

Which has stronger valuation & earnings, EVGN or APLT?

Summary

How does Evogene compare to Passage Bio?

Which has stronger earnings & valuation, EVGN or PASG?

Do insiders & institutionals believe in EVGN or PASG?

Is EVGN or PASG more profitable?

Does the media refer more to EVGN or PASG?

Which has more risk & volatility, EVGN or PASG?

Do analysts recommend EVGN or PASG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools